Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -82.0%. (1995–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $387 | $918625 | $3M | $5M | $40M | $80M | $139M | $22M | $5M | $3M | $3M |
| Enterprise Value | $43387 | $961625 | $15M | $1M | $20M | $67M | $123M | $19M | $18M | $22M | $-10722003 |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 704.15 | 12.46 | 3.05 | 1.47 | 3.04 |
| P/B Ratio | 0.00 | 0.09 | 0.82 | 0.53 | 0.95 | 1.15 | 1.86 | 0.68 | — | — | 1.00 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 622.00 | 10.66 | 11.93 | 10.98 | -10.86 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 93.6% | -490.7% | -1070.1% | 87.5% | 5.9% |
| Operating Margin | — | — | — | — | — | — | -12572.2% | -905.8% | -1518.4% | -1862.7% | -4035.9% |
| Net Profit Margin | — | — | — | — | — | — | -13876.3% | -1148.4% | -1242.2% | -1933.9% | -5589.7% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -82.0% | -82.0% | -302.8% | -151.1% | -121.4% | -41.9% | -38.4% | -92.9% | — | — | -401.7% |
| ROA | -18.2% | -18.2% | -57.7% | -69.6% | -72.1% | -26.1% | -23.1% | -33.5% | -282.8% | -146.1% | -120.1% |
| ROIC | -144.7% | -144.7% | -119.5% | -217.2% | -147.1% | -39.5% | -30.2% | -44.8% | — | — | — |
| ROCE | -99.0% | -99.0% | -54.9% | -78.5% | -87.5% | -27.8% | -23.7% | -35.8% | — | -256.9% | -109.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 4.96 | 0.23 | 0.07 | 0.05 | 0.08 | 0.12 | — | — | 3.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.00 | 3.69 | -0.39 | -0.46 | -0.19 | -0.22 | -0.05 | — | — | -1.66 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -6.63 | -6.63 | -404.82 | -764.57 | -679.90 | -259.53 | -54.51 | -13.57 | -8.90 | -14.68 | -11.04 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.45 | 0.45 | 1.35 | 3.00 | 4.77 | 2.96 | 3.05 | 1.24 | 0.19 | 0.54 | 3.69 |
| Quick Ratio | 0.45 | 0.45 | 1.35 | 3.00 | 4.77 | 2.96 | 3.05 | 1.24 | 0.19 | 0.54 | 3.69 |
| Cash Ratio | 0.31 | 0.31 | 1.08 | 2.51 | 4.54 | 2.76 | 2.89 | 1.22 | 0.15 | 0.42 | 3.50 |
| Asset Turnover | — | — | — | — | — | — | 0.00 | 0.01 | 0.44 | 0.21 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 71.5% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 100.0% | 71.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $52583 | $4306 | $700 | $550 | $348 | $243 | $33 | $8 | $3 | $3 |
Critical liquidity and delisting
As reported in financial statements, Windtree's ROIC has remained deeply negative, reaching -2.3% in 2025Q3, which underscores the company's inability to generate productive returns on invested capital while it continues to consume resources to fund its late-stage clinical development pipeline.
The consistent negative trend in ROIC, which plummeted to -138.3% in 2023Q2, suggests that the company's capital allocation has failed to create value for shareholders. Investors should monitor whether the shift toward orphan-like indications for istaroxime can eventually reverse this trend, though current figures indicate a structural inability to achieve positive returns.
Based on recent SEC filings, the company's current ratio has deteriorated to 0.33 as of 2025Q3, signaling a severe liquidity constraint that leaves the firm with virtually no margin of safety to cover its near-term obligations or ongoing clinical trial expenses.
The decline in the current ratio from a peak of 3.51 in 2023Q2 highlights the rapid depletion of liquid assets relative to liabilities. This precarious position suggests that the company is highly vulnerable to operational shocks, and any delay in securing additional financing could lead to a critical failure in meeting its contractual commitments.
According to quarterly data, the company's DPO has fluctuated wildly, reaching 19,359 days in 2025Q2, which suggests that the firm is likely stretching its payables to preserve cash in the face of an extremely limited liquidity position.
The extreme volatility in DPO metrics indicates that working capital management is driven by survival-oriented cash preservation rather than operational efficiency. Such reliance on extended payment terms may eventually strain relationships with critical CRO partners, potentially jeopardizing the execution of ongoing clinical trials.
As noted in financial analysis, the use of P/E or EV/EBITDA ratios is fundamentally inappropriate for Windtree, as the company lacks recurring revenue and positive earnings, rendering these standard valuation metrics meaningless for assessing its true clinical-stage potential.
Investors often misapply traditional multiples to biotech firms like Windtree, which obscures the reality that the company is a binary, clinical-stage play rather than an operating business. A more appropriate framework would involve probability-weighted net present value (rNPV) analysis of the istaroxime pipeline, rather than relying on distorted earnings-based multiples.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying WINT stock.
Windtree Therapeutics, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Windtree Therapeutics, Inc.'s return on equity (ROE) is -82.0%. The historical average is -171.0%.
Based on historical data, Windtree Therapeutics, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Windtree Therapeutics, Inc.'s current dividend yield is 100.00%.